TME Pharma

The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.

Dual inhibition of post-radiogenic angio- vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma – Interim data from the first expansion arm of the German Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Schaub C, Turiello R, Sperk E, Mildenberger I, Grau F, Paech D, Pietsch T, Mueller W, Grauer O, Renovanz M, Tabatabai G, Kebir S, Glas M, Bisdas S, Hambsch P, Seidel C, Hölzel M, Herrlinger U.
SNO 2022 November 18.
Poster Presentation

Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT unmethylated glioblastoma: Interim data from the German multicenter Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Seidel C, Schaub C, Turiello R, Sperk E, Grau F, Paech D, Link B, Mueller W, Tabatabai G, Sahm K, Kebir S, Pietsch T, Glas M, Bisdas S, Herrlinger U, Hölzel M.
ASCO 2022 June.
Poster Presentation

CXCL12 inhibition in MGMT unmethylated glioblastoma – Results of an early proof-of-concept assessment in the multicentric phase I/II GLORIA trial (NCT04121455).
Giordano FA, Layer JP, Leonardelli S, Friker L, Seidel C, Zeyen T, Schaub C, Sperk E, Grau F, Paech D, Radbruch A, Sahm K, Kebir S, Hambsch P, Pietsch T, Glas M, Bisdas S, Hölzel M, Herrlinge U.
SNO 2021 November.
Slide Presentation

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.
Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungelius JU, Baumann M, Mangasarian A, Halama N.
J Immunother Cancer 2021, 9, e002505.
read article on bmj.com

Final Top-Line Data: CXCL12 inhibitor NOX-A12 and pembrolizumab in microsatellite-stable, metastatic colorectal or pancreatic cancer.
Halama N, Williams A, Suarez-Carmona M, Schreiber J, Hohmann N, Prüfer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
ESMO 2020 (09), Poster Presentation.
Poster

Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab.
Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
AACR 2019 (04), Poster Presentation.
Poster

Correlation of clinical benefit with target neutralization and immune response in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab.
Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
ESMO 2018 (11), Poster Presentation.
Poster

Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
CRI-CIMT-EATI-AACR 2018 (09), Poster Presentation.
Poster

Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.
Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M.
Sci Rep. 2018, 8(1), 1841.
read abstract on pubmed.gov

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.
Oncotarget. 2017, 8(66), 109973-84.
read abstract on pubmed.gov

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib – dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M.
Leukemia. 2017, 31, 997-1000.
read article on pubmed.gov

SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Deng L, Stafford JH, Liu SC, Chernikova SB, Merchant M, Recht L, Martin Brown J.
Neoplasia. 2017, 19(1), 1-7.
read abstract on pubmed.gov

Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade.
Zboralski D, Hoehlig K, Eulberg D, Froemming A, Vater A
Cancer Immunol Res. 2017.
read article on aacrjournals.org

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.
Br J Haematol. 2017, 179(1), 36.
read abstract on pubmed.gov

Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ.
Am J Pathol. 2017.
read article on amjpathol.org

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.